RCUS - Arcus Biosciences, Inc.

NYSE - NYSE Delayed Price. Currency in USD

Arcus Biosciences, Inc.

3928 Point Eden Way
Hayward, CA 94545
United States
510 694 6200
http://www.arcusbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees139

Key Executives

NameTitlePayExercisedYear Born
Dr. Terry J. Rosen Ph.D.Co-Founder, Chairman & CEO341.2kN/A1960
Dr. Juan Carlos JaenCo-Founder, Pres & Director751.2kN/A1958
Dr. William J. GrossmanChief Medical Officer677.27kN/A1970
Mr. Jason BarkerVP of Fin. and Principal Financial & Accounting OfficerN/AN/A1971
Ms. Yvonne GehringVP of HR & OperationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc. Arcus Biosciences, Inc. was founded in 2015 and is based in Hayward, California.

Corporate Governance

Arcus Biosciences, Inc.’s ISS Governance QualityScore as of December 5, 2019 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.